Mulpleta

Active Ingredient(s): Lusutrombopag
FDA Approved: * July 31, 2018
Pharm Company: * SHIONOGI INC

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Mulpleta Overview

Lusutrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi under the trade name Mulpleta.[1][2][3] It was approved by FDA in July 2018.[4] References ^ Shionogi Receives Mark...

Read more Mulpleta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lusutrombopag

Recent Mulpleta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lusutrombopag
  • Tablet: 3mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Lusutrombopag or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 24 September 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA